Ravneet K. Hansi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ravneet K. Hansi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Christiane E. Whetstone
McMaster University
1 shared publication- Christiane E. Whetstone
Division of Respirology, Department of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada
1 shared publication Gail M. Gauvreau
McMaster University
1 shared publication- Gail M. Gauvreau
Division of Respirology, Department of Medicine McMaster University Hamilton Ontario Canada
1 shared publication Maral Ranjbar
McMaster University
1 shared publication- Maral Ranjbar
Division of Respirology, Department of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada
1 shared publication
Latest Publications
- 24 January 2026
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 20 (6) , 693-711
Recent updates on thymic stromal lymphopoietin as a therapeutic target for asthma
Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine shown to bridge innate and adaptive immunity, and orchestrates airway inflammation across both type 2 (T2)-high and T2-low asthma. Emerging evidence suggests that by functioning as an alarmin upstream of airway immune cells, TSLP integrates epithelial and immune signaling to initiate inflammation and structural remodeling, positioning it as a pivotal therapeutic target in asthma pathogenesis. This review summarizes the current understanding of TSLP biology and its roles in both T2- high and T2-low inflammation. Clinical data from tezepelumab treatment and emerging next-generation anti-TSLP agents, including bispecific antibodies, receptor antagonists and inhaled formulation, are evaluated for their potential to transform asthma management. Targeting TSLP represents a paradigm shift in asthma therapy, offering efficacy across diverse inflammatory endotypes, however with greater benefit in T2-high patients. Next-generation anti-TSLP agents aim to enhance potency, durability and tissue specificity, and combine with other agents for bi-specific therapy. Despite this progress in clinical development, key challenges remain, including understanding isoform-specific functions, improving biomarker-based patient stratification and assessing long-term safety of TSLP inhibition. As research advances, TSLP inhibition is expected to evolve from the strategy of single cytokine blockade into a personalized multi-pathway approach.
- 24 January 2026
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 20 (6) , 693-711
Recent updates on thymic stromal lymphopoietin as a therapeutic target for asthma
Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine shown to bridge innate and adaptive immunity, and orchestrates airway inflammation across both type 2 (T2)-high and T2-low asthma. Emerging evidence suggests that by functioning as an alarmin upstream of airway immune cells, TSLP integrates epithelial and immune signaling to initiate inflammation and structural remodeling, positioning it as a pivotal therapeutic target in asthma pathogenesis. This review summarizes the current understanding of TSLP biology and its roles in both T2- high and T2-low inflammation. Clinical data from tezepelumab treatment and emerging next-generation anti-TSLP agents, including bispecific antibodies, receptor antagonists and inhaled formulation, are evaluated for their potential to transform asthma management. Targeting TSLP represents a paradigm shift in asthma therapy, offering efficacy across diverse inflammatory endotypes, however with greater benefit in T2-high patients. Next-generation anti-TSLP agents aim to enhance potency, durability and tissue specificity, and combine with other agents for bi-specific therapy. Despite this progress in clinical development, key challenges remain, including understanding isoform-specific functions, improving biomarker-based patient stratification and assessing long-term safety of TSLP inhibition. As research advances, TSLP inhibition is expected to evolve from the strategy of single cytokine blockade into a personalized multi-pathway approach.
- Open Access
- 11 October 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (10) , 2312
Regulation of Airway Epithelial-Derived Alarmins in Asthma: Perspectives for Therapeutic Targets
Asthma is a chronic respiratory condition predominantly driven by a type 2 immune response. Epithelial-derived alarmins such as thymic stromal lymphopoietin (TSLP), interleukin (IL)-33, and IL-25 orchestrate the activation of downstream Th2 cells and group 2 innate lymphoid cells (ILC2s), along with other immune effector cells. While these alarmins are produced in response to inhaled triggers, such as allergens, respiratory pathogens or particulate matter, disproportionate alarmin production by airway epithelial cells can lead to asthma exacerbations. With alarmins produced upstream of the type 2 inflammatory cascade, understanding the pathways by which these alarmins are regulated and expressed is critical to further explore new therapeutics for the treatment of asthmatic patients. This review emphasizes the critical role of airway epithelium and epithelial-derived alarmins in asthma pathogenesis and highlights the potential of targeting alarmins as a promising therapeutic to improve outcomes for asthma patients.
- 11 October 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (10) , 2312
Open AccessRegulation of Airway Epithelial-Derived Alarmins in Asthma: Perspectives for Therapeutic Targets
Asthma is a chronic respiratory condition predominantly driven by a type 2 immune response. Epithelial-derived alarmins such as thymic stromal lymphopoietin (TSLP), interleukin (IL)-33, and IL-25 orchestrate the activation of downstream Th2 cells and group 2 innate lymphoid cells (ILC2s), along with other immune effector cells. While these alarmins are produced in response to inhaled triggers, such as allergens, respiratory pathogens or particulate matter, disproportionate alarmin production by airway epithelial cells can lead to asthma exacerbations. With alarmins produced upstream of the type 2 inflammatory cascade, understanding the pathways by which these alarmins are regulated and expressed is critical to further explore new therapeutics for the treatment of asthmatic patients. This review emphasizes the critical role of airway epithelium and epithelial-derived alarmins in asthma pathogenesis and highlights the potential of targeting alarmins as a promising therapeutic to improve outcomes for asthma patients.